Aptamer-Based HSA and GHSA Detection Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting human serum albumin (HSA) and glycated human serum albumin (GHSA) lack specificity, relying on dye-binding methods and immunochemical assays that are time-consuming and prone to interference, making them unsuitable for accurate detection in abnormal conditions such as kidney failure.
Innovation Solution
Development of aptamers specifically binding to HSA and GHSA, selected through the SELEX method, which offer higher affinity and stability compared to traditional antibodies, enabling more precise and efficient detection and potential applications in diagnostic and therapeutic fields.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If dye-binding methods or immunochemical assays are used for detecting HSA and GHSA, then detection can be performed, but the methods lack specificity and are prone to interference in abnormal conditions
Solution Approach 1:
The patent uses aptamers as synthetic copies that mimic antibody binding functionality. These DNA/RNA aptamers are selected through SELEX to specifically bind HSA and GHSA, providing a more specific detection mechanism that reduces interference from other proteins and substances in abnormal conditions like kidney failure.
Solution Approach 2:
The patent changes the binding parameter from traditional antibodies or dyes to nucleic acid-based aptamers. This parameter change enables higher specificity through sequence-specific recognition and allows for better discrimination between HSA and GHSA, improving measurement precision and reliability.
2Productivity
If traditional immunochemical assays are used, then HSA and GHSA can be detected, but the process is time-consuming
Solution Approach 1:
The patent replaces time-consuming antibody-based immunochemical assays with aptamer-based detection. The synthetic aptamers can be produced rapidly through SELEX and offer faster binding kinetics, reducing the overall assay time while maintaining detection capability.
Solution Approach 2:
The patent employs synthetic aptamers that can be easily synthesized and replaced compared to biological antibodies. These short-living synthetic molecules eliminate the need for complex antibody production and purification steps, significantly reducing assay time and increasing productivity.
3Measurement precision
If monoclonal antibodies are used to bind GHSA, then specific binding is achieved, but the complexity of production and stability issues arise
Solution Approach 1:
The patent creates synthetic aptamer copies that replicate the specific binding function of monoclonal antibodies without requiring complex biological production systems. The SELEX process generates DNA/RNA aptamers with high GHSA specificity through in vitro selection, eliminating the need for animal immunization and antibody purification.
Solution Approach 2:
The patent uses inexpensive synthetic nucleic acid aptamers instead of expensive monoclonal antibodies. These synthetic molecules are chemically synthesized, easily stored, and can be rapidly produced, greatly reducing production complexity while maintaining binding specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The selected aptamers demonstrate enhanced binding affinity and specificity for HSA and GHSA, facilitating improved monitoring and drug development for diabetes mellitus and Alzheimer's disease, as well as potential use in analyzing HSA and GHSA in various secretions and treating diabetes-related complications.
Implementation Method 1
aptamers that specifically bound HSA and GHSA
Implementation Method 2
selected aptamers that specifically bound to HSA and GHSA, having a high affinity binding
Data Source
AI summary
This invention is about the selection and development of aptamers that specifically bound HSA and GHSA. HSA and GHSA are associated with diabetes mellitus. The length of selected aptamers are around 46-106 bases, in which aptamers against HSA are consisting of 46-106 bases and aptamers against GHSA are consisting of 49-71 bases. All selected aptamers against HSA and GHSA can be potentially applied for detection and monitoring of diabetes mellitus in combination with blood glucose and HbA1C level. They also can applied in the drug development and drug delivery system in the diabetes mellitus and Alzheimer disease. In addition, chemical or fluorescence labeled these aptamers can be used for study function and location of HSA and GHSA.